Login
BRICS
Independence Day
Social Media
Floods
Formula 1
Natural Disasters
Artificial Intelligence
Donald Trump
Tennis
Vladimir Putin
Israel-Hamas Conflict
Apple
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

healtheconomics.com image

News from healtheconomics.com

Information about healtheconomics.com

Where is healtheconomics.com located?healtheconomics.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top healtheconomics.com News

CVS Benefits Arm Slapped With $95M In Medicare Overbilling Judgment — Penalty Could Triple By Stocktwits
Trees · Philadelphia

CVS Benefits Arm Slapped With $95M In Medicare Overbilling Judgment — Penalty Could Triple By Stocktwits

65% Center coverage: 14 sources
PHILADELPHIA, June 27, 2025 /PRNewswire/ -- Berger Montague PC and Miller Shah LLP, on behalf of their whistleblower client, are pleased to announce that on June 25, 2025, a Pennsylvania federal judge found pharmacy benefits manager Caremark and related entities…See the Story
AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
Cancer

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

87% Center coverage: 8 sources
AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders. The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.See the Story
Intuitive’s Da Vinci 5 Surgical System Receives CE Mark
European Union

Intuitive’s Da Vinci 5 Surgical System Receives CE Mark

60% Center coverage: 5 sources
Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures...See the Story

UCSF to Lay Off About 200 Employees Amid ‘Serious Financial Challenges’

67% Center coverage: 3 sources
(KRON) -- Approximately 200 University of California, San Francisco (UCSF) healthcare employees are being laid off, the university announced in a press release Wednesday. UCSF called it a difficult but necessary decision to combat "serious financial challenges" the hospital is facing. "We are deeply grateful for their contributions. Impacted employees will receive full UC benefits, including severance and support with career transition," UCSF sa…Unions · San FranciscoSee the Story

Uncertain Future for Trump's Most Favored Nation Model to Lower Drug Prices

Since Donald Trump’s executive order in May, which promised to reduce U.S. prescription drug prices by 30% to 80%, the administration has not released any specifics on implementing the “most favored nation” model. This model aims to tie U.S. drug prices to those in comparably wealthy nations, yet pharmaceutical executives have noted a lack of clarity from the administration. The only publicly known detail is that prices would be benchmarked agai…Donald Trump · United StatesRead Article

First German Patient Receives HEMGENIX Gene Therapy for Haemophilia B

In a groundbreaking development, the first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at Hannover Medical School. Developed by CSL Behring, HEMGENIX is the first gene therapy of its kind approved in Europe for adults with severe forms of the disorder and represents a significant advancement in addressing the genetic cause of haemophilia B. Christian Schepperle of Interessengemeinschaft Hämophiler e.…Lower Saxony · Lower SaxonyRead Article

CMS to Finalize Drug Price Transparency Rule in 2025, Aiming to Lower Costs and Increase Accountability

On June 24, U.S. Surgeon General Mehmet Oz announced that the Centers for Medicare & Medicaid Services (CMS) will finalize a rule this year requiring insurers to publicly report the net prices paid for prescription drugs. Originally proposed under the Trump administration and withdrawn in 2022, the rule has been revived as part of the Biden administration’s drug pricing reform efforts. If finalized, the rule would mandate both public and private…Mehmet Oz · United StatesSee the Story

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its late stage at diagnosis and its resistance to chemotherapy…NHS · EnglandSee the Story

Biotech’s Turning Point: for Every Challenge, an Opportunity in Disguise

100% Center coverage: 1 sources
As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.Biotech · United StatesSee the Story

Breyanzi Demonstrates Promising Efficacy in Phase II TRANSCEND FL Trial for Relapsed Marginal Zone Lymphoma

In the Phase II TRANSCEND FL trial, Breyanzi (lisocabtagene maraleucel) demonstrated significant efficacy in treating patients with relapsed or refractory marginal zone lymphoma (MZL). With a remarkable overall response rate of 95.5% and a complete response rate of 62.1%, Breyanzi shows promise as an effective treatment for this challenging condition. The trial, which is the largest of its kind evaluating chimeric antigen receptor (CAR) T-cell t…Florida, United States · FloridaRead Article

Senate Excludes Orphan Cures Act From Trump's Tax Bill, Impacting Biopharma

The biopharma industry faced a setback as the Senate’s version of the One Big Beautiful Bill Act, linked to President Donald Trump’s tax reforms, excluded the Orphan Cures Act, a provision aimed at amending an Inflation Reduction Act (IRA) clause affecting rare disease treatments. This bipartisan act sought to exempt drugs with multiple rare disease indications from Medicare’s price negotiations, an exemption currently applicable only to drugs t…Donald Trump · United StatesSee the Story

Breaking News Topics Related to healtheconomics.com

Health icon

Health

Donald Trump icon

Donald Trump

Medical icon

Medical

United States icon

United States

News
For You
SearchBlindspotLocal